OPEN ACCESS ISSN: 2835-9496 Bowden RG (2023): 354
DOI: 10.47991/2835-9496/AJCMR-112

Short Communication American Journal of Clinical and Medical Research

Research and Clinical Implications for the Inclusion of Uric Acid as a Component of Metabolic Syndrome

Rodney G. Bowden, PhD*

Professor and Brown Foundation Endowed Chair, Department of Public Health, Baylor University

***Corresponding author:** Rodney G. Bowden, PhD, Professor and Brown Foundation Endowed Chair, Department of Public Health, Baylor University. Email: Rodney_Bowden@baylor.edu

Citation: Bowden RG (2023) Research and Clinical Implications for the Inclusion of Uric Acid as a Component of Metabolic Syndrome. Ameri J Clin Med Re: AJCMR-112.

Received Date: 26 October, 2023; **Accepted Date:** 30 October, 2023; **Published Date:** 06 November, 2023

Metabolic syndrome is a complex and multifactorial medical condition that encompasses a cluster of interconnected risk factors for cardiovascular disease, type 2 diabetes, chronic kidney disease and other metabolic disorders [1]. Currently, the definition of metabolic syndrome includes central obesity, hypertension, dyslipidemia, and impaired glucose metabolism [2]. However, there is growing evidence to suggest that uric acid, a metabolic waste product primarily associated with gout, should be considered as an additional component of metabolic syndrome [3–7].

Uric acid is the end-product of purine metabolism from dietary sources or cellular turnover with a downstream effect of producing uric acid [8]. Elevated uric acid levels are typically associated with gout, a painful inflammatory joint condition, however, recent studies have reported on uric acid's broader metabolic implications [9,10]. High levels of uric acid or hyperuricemia, have been linked to several metabolic abnormalities, including insulin resistance, hypertension, dyslipidemia, particularly high triglyceride levels and low HDL cholesterol levels [11] and obesity. Uric acid also plays a role in oxidative stress and inflammation, two important factors in the development of cardiovascular disease, diabetes and risk factors for metabolic syndrome [12]. This emerging body of evidence highlights the potential relevance of uric acid as a key player in the development of metabolic syndrome. In one of our studies [13], we demonstrated that controlling for known metabolic syndrome risk factors, uric acid emerged as an independent risk factor with an additional study also demonstrating this relationship in those with and without metabolic syndrome [14].

Including uric acid as a component of metabolic syndrome has several clinical implications [15,16]. Inclusion of uric acid levels could provide a more comprehensive understanding of the syndrome's pathophysiology, which could aid in more accurate diagnoses and risk stratification. Clinicians would be better equipped to identify individuals at elevated risk for cardiovascular disease, chronic kidney disease and diabetes by considering uric acid levels in combination with the existing components of metabolic syndrome. Additionally, targeting hyperuricemia as a therapeutic strategy may prove beneficial in preventing and managing metabolic syndrome with a novel therapeutic use approach. For example, allopurinol, a medication commonly used to lower uric acid levels in gout patients, has promise in improving insulin sensitivity and reducing blood pressure and thereby reduce the risk of developing metabolic syndrome. Early identification of hyperuricemia can help healthcare professionals implement targeted interventions and more personalized treatment plans such as dietary changes and new use of medications to lower uric acid levels and potentially reduce the risk of developing metabolic syndrome and its associated complications. Incorporating uric acid measurements into the assessment of metabolic syndrome allows for more precise risk stratification among patients. Those with hyperuricemia may have a higher risk of cardiovascular events and other metabolic syndrome-related complications, helping clinicians identify individuals who may benefit from more aggressive treatment and lifestyle modifications. Identifying hyperuricemia as a component of metabolic syndrome provides clinicians with another therapeutic target. Lowering uric acid levels through dietary modifications, lifestyle changes, or medications could potentially contribute to better glycemic control and blood pressure management. Finally, monitoring uric acid levels in at-risk individuals can facilitate early intervention and prevention strategies. By identifying hyperuricemia in its earlier stages, healthcare providers can address the root causes and help patients make lifestyle changes that may prevent the full development of metabolic syndrome. This proactive approach can potentially reduce the burden of long-term complications. By recognizing the role of uric acid in metabolic syndrome, healthcare providers may have additional tools to lower metabolic complications.

Future research should aim to further elucidate the strength of relationship between uric acid and metabolic syndrome and if it would further clinical treatment in patients. Longitudinal studies and randomized controlled trials are needed to establish whether lowering uric acid levels can prevent or mitigate the development of metabolic syndrome and its associated complications. Additionally, a standardized definition and diagnostic criteria for including uric acid in the metabolic syndrome criteria should be established.

Evidence suggests that uric acid should be considered as a component of metabolic syndrome due to its strong associations with the individual components of the syndrome and its potential role in its pathogenesis. By incorporating uric acid into the metabolic syndrome definition, we may enhance our understanding of the condition, improve risk assessment, and develop novel therapeutic approaches to tackle this critical public health issue.

References

1. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. *Diabetes Care*. 2009;32(9):1737-1742. doi:10.2337/dc09-0288
2. Bartziokas K, Papaioannou AI, Loukides S, et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD. *European Respiratory Journal*. 2014;43(1):43-53. doi:10.1183/09031936.00209212
3. Crawley WT, Jungels CG, Stenmark KR, Fini MA. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. *Redox Biology*. 2022; 51:102271. doi:10.1016/j.redox.2022.102271
4. Georgoulis M, Mikhailidis DP, Panagiotakos DB. Are serum uric acid levels predictors of cardiovascular risk? An update. *Current Opinion in Cardiology*.:10.1097/HCO.0000000000001029. doi:10.1097/HCO.0000000000001029
5. Jena L, Singh S, Nayak SR, Behera B, Panigrahi R, Panigrahi SK. Evaluation of the Serum Uric Acid Level as an Early Predictor of Mortality Among the Patients with Myocardial Infarction: A Prospective Study. *International Journal of Scientific Research in Dental and Medical Sciences*. 2022;4(2):81-86. doi:10.30485/ijsrdms.2022.340472.1293
6. Khodabandeh N, Taziki E, Alirezaei T. Serum uric acid as a predictor of cardio- and cerebro-vascular diseases in maintenance hemodialysis patients. *Romanian Journal of Internal Medicine*. 2022;60(2):115-122. doi:10.2478/rjim-2021-0039
7. Kim HK, Lee M, Lee Y ho, Lee BW, Cha BS, Kang ES. Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes. *Frontiers in Cardiovascular Medicine*. 2021;8. Accessed March 20, 2023. https://www.frontiersin.org/articles/10.3389/fcvm.2021.775753
8. Angelico F, Baratta F, Coronati M, Ferro D, Del Ben M. Diet and metabolic syndrome: a narrative review. *Intern Emerg Med*. Published online March 16, 2023. doi:10.1007/s11739-023-03226-
9. Singh C, Jain S, Dhawan V, Kalra N, Kumari S. Uric acid as a predictor of endothelial dysfunction in patients with metabolic syndrome. *Arch Endocrinol Metab*. 2020; 64:810-815. doi:10.20945/2359-3997000000298
10. Uduagbamen PK, Ogunkoya JO, AdebolaYusuf AO, et al. Hyperuricemia in Hypertension and Chronic Kidney Disease: Risk Factors, Prevalence and Clinical Correlates: A Descriptive Comparative Study. *International Journal of Clinical Medicine*. 2021;12(9):386-401. doi:10.4236/ijcm.2021.129035
11. Richardson K, Richardson L, Bowden R. Association of High-Density Lipoprotein Cholesterol, Renal Function, and Metabolic Syndrome: An Assessment of the 2013–2018 National Health and Nutrition Examination Surveys. *Kidney and Dialysis*. 2022; 2:419-432. doi:10.3390/kidneydial2030037
12. Zhou Y, Zhao M, Pu Z, Xu G, Li X. Relationship between oxidative stress and inflammation in hyperuricemia. *Medicine (Baltimore)*. 2018;97(49): e13108. doi:10.1097/MD.0000000000013108
13. Bowden RG, Richardson KA, Richardson LT. Uric acid and metabolic syndrome: Findings from national health and nutrition examination survey. *Front Med (Lausanne)*. 2022; 9:1039230. doi:10.3389/fmed.2022.1039230
14. Rodney G B, Kathleen A R, Luke T R. Uric Acid as a Novel Component of Metabolic Syndrome. *Int J Clin Cardiol*. 2023;10(3). doi:10.23937/2378-2951/1410278
15. King C, Lanaspa MA, Jensen T, Tolan DR, Sánchez-Lozada LG, Johnson RJ. Uric Acid as a Cause of the Metabolic Syndrome. Published online January 23, 2018. doi:10.1159/000484283
16. Raya-Cano E, Vaquero-Abellán M, Molina-Luque R, De Pedro-Jiménez D, Molina-Recio G, Romero-Saldaña M. Association between metabolic syndrome and uric acid: a systematic review and meta-analysis. *Sci Rep*. 2022;12:18412. doi:10.1038/s41598-022-22025-2